Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection testing, announced today that six studies utilizing their patented PhasED-Seq™ technology will be presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH 2023) taking place December 9-12, 2023, in San Diego, California.
| |
| [08-November-2023] |
| AURORA, Colo., Nov. 8, 2023 /PRNewswire/ -- Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection testing, announced today that six studies utilizing their patented PhasED-Seq™ technology will be presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH 2023) taking place December 9-12, 2023, in San Diego, California. Four of these studies have been accepted as oral presentations.
The PhasED-Seq MRD platform is a ctDNA test that detects minimal residual disease (MRD) with higher levels of sensitivity and specificity compared to first-generation MRD technologies. In patients with lymphomas, this could enable the earlier detection of residual disease in patients who are prone to relapse after first-line therapy. Recent studies have shown that PhasED-Seq’s sensitivity and specificity exceeds that of standard of care imaging (e.g., PET/CT) allowing for more accurate response assessment in patients with DLBCL. Additionally, exploratory studies have demonstrated that PhasED-Seq’s high sensitivity detected future relapse an average of 10 months sooner than imaging. Building upon these findings, Foresight and its partners will present new data at ASH 2023 that further supports the utility of Foresight’s ultrasensitive PhasED-Seq MRD platform for accurate treatment response assessment. These data sets demonstrate the superiority of PhasED-Seq relative to standard of care PET/CT imaging for response assessment in multiple clinical settings, as well as its potential utility as a biomarker for treatment selection. “We are thrilled to have been selected by the ASH Program Committee to share data from these impactful studies that utilize Foresight’s PhasED-Seq MRD technology,” said Jake Chabon, PhD, CEO and co-founder of Foresight Diagnostics. “Our goal at Foresight Diagnostics is to improve patient care by providing researchers with actionable data and insights that we hope will pave the way for the next generation of lymphoma care utilizing ctDNA measures. We are particularly excited by the promise of PhasED-Seq based MRD assessment as an endpoint in lymphoma clinical trials which could lead to accelerated approvals of novel therapies, thus getting potentially life-saving treatments to patients faster. We are grateful to all the collaborators and presenters for their important work at the 2023 ASH Annual Meeting.” Podium Presentations: Abstract Number: 225 Abstract Number: 192 Abstract Number: 187 Abstract Number: 69 Poster Presentations: Abstract Number: 3133 Abstract Number: 1626 For more information, visit us at booth #2014 or email us at info@foresight-dx.com to arrange a meeting. About Foresight Diagnostics Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. The company has developed a novel liquid biopsy testing platform for the measurement of minimal residual disease (MRD). The improved sensitivity of the Foresight MRD assays can provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with solid tumors and B-cell malignancies. For more information, please visit foresight-dx.com and follow us on Twitter and LinkedIn. About PhasED-Seq The Foresight MRD platform is based on the Phased variant Enrichment and Detection by Sequencing (PhasED-Seq) technology. PhasED-Seq lowers the error profile of mutation detection in sequencing data by requiring the concordant detection of two separate non-reference events in an individual DNA molecule. By detecting more than one mutation, PhasED-Seq can more accurately distinguish tumor-derived cell free DNA (i.e., ctDNA) from healthy cell free DNA – enabling detection of ctDNA at levels below one part-per-million (<0.0001%). PhasED-Seq has been extensively tested in thousands of patients. Media Contact Information 720-443-3658
SOURCE Foresight Diagnostics |
View original content to download multimedia:
